Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations by Paes, B. et al.
ORIGINAL ARTICLE
Respiratory hospitalizations and respiratory syncytial virus
prophylaxis in special populations
B. Paes & I. Mitchell & A. Li & K.L. Lanctôt
Received: 20 September 2011 /Accepted: 7 December 2011 /Published online: 28 December 2011
# The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract Palivizumab utilization, compliance, and out-
comes were examined in infants with preexisting medical
diseases within the Canadian Registry Database (CARESS)
to aid in developing guidelines for potential “at-risk” infants
in the future. Infants who received ≥1 dose of palivizumab
during the 2006–2010 respiratory syncytial virus (RSV)
seasons at 29 sites were recruited and utilization, compli-
ance, and outcomes related to respiratory infection/illness
(RI) events were collected monthly. Hazard ratios (HRs) and
95% confidence intervals (CIs) were calculated for prema-
ture infants ≤35 completed weeks gestational age (GA) who
met standard approval criteria (group 1) compared to those
with medical disorders (group 2) using Cox proportional
hazards regression models with adjustment for potential
confounding factors. Of 7,339 registry infants, 4,880 were
in group 1 and 952 in group 2, which included those with
Down syndrome (20.3%), upper airway anomalies (18.7%),
pulmonary diseases (13.3%), and cystic fibrosis (12.3%).
Group 2 were older at enrolment (10.2±9.2 vs. 3.5±
3.1 months, p<0.0005), had higher GA (35.9±6.0 vs. 31.0
±5.4 weeks, p<0.0005), and were less compliant with
treatment intervals (69.4% vs. 72.6%, p00.048). A greater
proportion of group 2 infants were hospitalized for RI (9.0%
vs. 4.2%, p<0.0005) and RSV (2.4% vs. 1.3%, p00.003)
(unadjusted). Being in group 2 was associated with an
increased risk of RI (HR02.0, 95%CI 1.5–2.5, p<0.0005),
but not RSV hospitalization (HR01.6, 95%CI 0.9–2.8, p0
0.106). In infants receiving palivizumab, those with under-
lying medical disorders, though not currently approved for
prophylaxis, are at higher risk for RI events compared with
preterm infants. However, risk of RSV hospitalizations is
similar.
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Introduction
Respiratory syncytial virus (RSV) is an important viral
respiratory pathogen in children <2 years of age in terms
of morbidity and societal costs. Infections occur seasonally,
with peaks during the winter months [21]. In Canada, the
RSV season begins between October and December and
typically ends between March and May of the following
year.
Palivizumab is a humanized monoclonal antibody [25,
48] that has proven efficacy and safety in both premature
infants ≤32 weeks gestation and in children with broncho-
pulmonary disease (BPD) [24]. It is also equally effective in
infants who completed 33–35 weeks gestation and who
have additional risk factors that have been utilized to target
prophylaxis cost-effectively in moderate- to high-risk
infants in this cohort[12, 16, 17, 24, 26, 33, 39, 41]. A
large-scale randomized trial also showed a 45% RSV-
positive hospitalization rate reduction in patients with
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(CHD) [15]. Several studies have since demonstrated the
efficacy of palivizumab in infants <35 weeks gestational age
(GA) and those with BPD/chronic lung disease (CLD) [40].
The Palivizumab Outcomes Registry reviewed 19,548
infants who received palivizumab between 2000 and 2004
[17] and found an RSV-positive hospitalization rate of 1.3%
overall. The cohort comprised 9.1% subjects with congeni-
tal airway anomalies and severe neuromuscular disorders
and there was a steady decline in RSV-positive hospitaliza-
tion from 2.9% in the 2000–2001 season to 0.7% in the
2003–2004 season.
It is important to study whether a drug is being used
according to predetermined risk factors and that usage com-
plies with provincial and national recommendations [9–11].
High-risk subjects targeted for palivizumab include prema-
ture infants born ≤32 weeks GAwho are ≤6 months of age at
the start of the RSV season, children <2 years of age with
hemodynamically significant CHD, and children <2 years of
age with BPD/CLD that require oxygen or medical therapy
6 months prior to the onset of the RSV season. Moderate- to
high-risk 32–35 weeks GA infants may also receive prophy-
laxis based on validated Canadian and European risk scor-
ing tools [39, 41]. Palivizumab may also be prescribed for
patients with significant underlying medical conditions such
as congenital airway anomalies, neuromuscular disease,
immunocompromise, and Down syndrome, if they are con-
sidered at high risk of serious sequelae from RSV infection
[2, 11, 37]. While the cost-effectiveness of palivizumab has
been studied for approved indications, the cost-effectiveness
in special populations is unknown. This is an important
issue as the acquisition costs for palivizumab are substantial,
but must be balanced against the cost of hospitalizations and
lost quality of life. However, in the absence of established
guidelines for routine prophylaxis of specific medical dis-
orders, physicians are currently shouldered with the onus of
requesting palivizumab based on emerging scientific infor-
mation and perceived individual risk benefit vs. harm.
The ministry of health in each Canadian province appro-
ves RSV prophylaxis for special populations of infants on a
case-by-case basis adjudicated by provincial advisory
groups. For example, infants with Down syndrome both
with and without CHD [4–6] and infants with cystic fibrosis
[20, 23, 31, 45] are considered to be at high risk for RSV
infection with consequential respiratory morbidity. Many
physicians are also strongly advocating for the use of RSV
prophylaxis in special populations worldwide despite the
restricted guidelines published by pediatric advisory bodies
nationally and internationally [35].
The Canadian Registry Database (CARESS) was estab-
lished in 2005 and is a Canadian database of infants who
have received at least one dose of palivizumab during the
RSV season across 29 sites [33]. The primary objective of
this study was to compare the utilization, compliance, and
health outcomes of a palivizumab-prophylaxed cohort with
preexisting medical illnesses who are not currently approved
for passive RSV immunization to that of prophylaxed
infants ≤35 weeks gestation without underlying medical
disorders who routinely qualify for RSV prophylaxis
according to recommended guidelines. Collection of long-
term data on seasonality, risk factors, and outcomes are
necessary to evaluate the impact of prophylaxis on the
incidence of RSVinfections, minimize healthcare resources,
and identify which pediatric subgroups receive palivizumab
prophylaxis [27, 36]. The latter goal is important in order to
document whether current prophylaxis administration aligns
with existing position statements and such data could also
influence future recommendations and set the stage for
research initiatives in special populations.
Methods
The CARESS study is a prospective, observational study.
The current paper presents a post hoc subanalysis of the
main study. Any child receiving at least one dose of palivi-
zumab was eligible for inclusion. Children were excluded if
a parent or legal guardian could not communicate in either
English or French or if the child had received palivizumab
as part of a clinical trial during the study period. This study
was approved by the appropriate ethics committee at all sites
and, therefore, has been performed in accordance with
the ethical standards laid down in the Declaration of
Helsinki.
Data collection
Subjects were enrolled by the treating physician and/or
research nurse. Following consent, baseline data were
obtained on patient demographics, prior medical history,
neonatal course, and details of palivizumab administration.
Infants were categorized into the following indications:
prematurity (≤35 completed weeks gestation), BPD/CLD,
hemodynamically significant CHD, or other (e.g., congeni-
tal airway anomalies and neuromuscular impairments).
Follow-up telephone interviews were conducted monthly
until the end of the RSV season, obtaining data on palivi-
zumab administration, changes in baseline data, and specif-
ics of RIs.
In the event of a hospitalization, relevant hospital records
were reviewed by the site’s research nurse for hospitaliza-
tion criteria, length of stay, days on respiratory support and/
or intubation, potential concomitant illnesses, type of diag-
nostic RSV test, and medical diagnosis at the time of hos-
pital admission as reported in the discharge summary.
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center, was then electronically logged into the registry in an
anonymous fashion.
Statistical analyses
Data were analyzed using standard descriptive methods,
SPSS version 19.0 (SPSS Inc., Chicago, IL, USA). Prema-
ture infants ≤35 completed weeks GA without preexisting
illness who met standard approval criteria [9] (group 1) were
compared to those >35 completed weeks GA without BPD
or CHD delineated by provincial guidelines, but who had
underlying medical disorders (group 2). The primary end-
points were hospitalizations for both respiratory infection/
illness (RI) and RSV. An RSV-positive hospitalization was
defined as any hospitalization during which it was deter-
mined that the infant had an RSV-positive infection by rapid
test, polymerase chain reaction, and/or viral culture. Hazard
ratios (HRs) and 95% confidence intervals (CIs) were cal-
culated for both RI and RSV-positive hospitalizations in
premature infants ≤35 completed weeks GA who met stan-
dard approval criteria (group 1) compared to those with
medical disorders (group 2) using Cox proportional hazards
regression models with adjustment for potential confound-
ing factors using a backward conditional method. A sub-
analysis was conducted, repeating the above analysis but
comparing infants in group 2 with infants prophylaxed for
all other indications (prematurity, as well as BPD/CLD and
CHD) (n06387), as infants with BPD/CLD and CHD could
potentially resemble group 2 infants in terms of their under-
lying cardiorespiratory morbidities.
Results
Subjects
Subjects were enrolled between October 2006 and May
2010. A total of 7,339 infants have been recruited in 29
Canadian sites: 5 from Western Canada (British Columbia,
Alberta, Manitoba, and Saskatchewan), 22 from Central
Canada (Ontario, Quebec), and 2 from Eastern Canada
(New Brunswick, Newfoundland, Nova Scotia, and Prince
Edward Island). The distribution of infants in the registry
reflects the population distribution across Canada [43]. Fur-
ther details of the CARESS registry have been published
elsewhere [33]. Of the 7,339 patients, 5,832 were included
in the analysis, with 4,880 subjects categorized in group 1
and 952 in group 2. The remaining 1,507 infants were
excluded from the analysis as they were given prophylaxis
for BPD/CLD and/or CHD or were classified under multiple
categories.
Demographic information and the neonatal course are
shown in Table 1. Group 2 infants were heavier and older
at both birth and enrolment. A greater proportion of group 2
infants was in daycare and had siblings, though group 1
patients were more likely to be multiples. Group 1 infants
also had more tobacco exposure. The two groups had, on
average, similar lengths of hospital stay after birth. Group 1
infants had a more complicated course, with significantly
greater proportions requiring respiratory support, oxygen
therapy, and documented necrotizing enterocolitis. However,
Group 2 patients tended to require longer durations of both
respiratory support and oxygen therapy.
Infants in Group 2 did not meet standard approval criteria
delineated by provincial RSV prophylaxis guidelines (>35
completed weeks GA, without BPD or CHD). Patients in-
cluded those with Down syndrome (193, 20.3%), congenital
airway anomalies (178, 18.7%), pulmonary disease such as
lung hypoplasia, chylothorax, and mediastinal masses (127,
13.3%), cystic fibrosis (117, 12.3%), neuromuscular disor-
ders (78, 8.2%), multiple system disorders involving chro-
mosomal and dysmorphology syndromes (57, 6.0%),
severe CHD aged >2 years (22, 2.3%), immunocompro-
mise (17, 1.8%), and others (163, 17.1%), e.g., infants
with obstructive sleep apnea, severe failure to thrive, or
metabolic disease.
Over the RSV seasons, there has been a steady, propor-
tionate increase in group 2 patients, from 5.6% (69 out of
1,224) in 2006–2007, to 10.4% (175 out of 1,686) in 2007–
2008, to 12.2% (246 out of 2,016) in 2008–2009, and to
19.1% (462 out of 2,413) in 2009–2010. Subanalysis indi-
cates a marked increase in Down syndrome infants (χ
20
24.277, df03, p<0.0005), as well as in the “other” category
(χ
2012.667, df03, p00.05) (Fig. 1).
Of the 5,832 included patients, 291 patients (5.0%) were
withdrawn. There was no significant difference between
groups in the proportion of patients withdrawn (5.0% vs.
4.9%, p01.00). The majority were lost to follow-up
(51.4%), with no significant differences between the two
groups. A total of eight infants (four in each group) died
over the course of the study for causes thought not directly
related to palivizumab. There was one fatality in a group 2
infant that was reported as being directly associated with an
RSV-related hospitalization.
Utilization and compliance
A total of 22,465 injections were administered to infants in
both groups. Infants received, on average, 3.6±1.5 injec-
tions; group 2 infants received more injections than group 1
infants (3.8±1.7 vs. 4.2±1.6, t0−7.895, df01397, p<
0.0005). Group 2 infants were more likely to receive their
first injection in the first half of the season (68.9% vs.
58.4%, χ
2038.580, df01, p<0.0005). The majority
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information and neonatal course
aProphylaxed infants ≤35 weeks
gestation without underlying
medical disorders who routinely
qualify for RSV prophylaxis
according to recommended
guidelines
bProphylaxed cohort with preex-
isting medical illnesses who are
not currently approved for
passive RSV immunization
Group 1
a, n04,880 Group 2
b, n0952 p value
Demographic information
Male (%) 2,751 (56.4) 529 (55.6) 0.829
Caucasian (%) 3,389 (69.4) 711 (74.7) 0.001
In daycare (%) 65 (1.3) 86 (9.0) <0.0005
Mean GA (weeks±SD) 31.0±5.4 35.9±6.0 <0.0005
Mean birth weight (g±SD) 1,597±660 2,751±1,708 <0.0005
Mean enrolment age (months±SD) 3.5±3.1 10.2±9.2 <0.0005
Mean enrolment weight (g±SD) 4,095±2,335 7,292±3,044 <0.0005
With siblings (%) 2,877 (59.0) 606 (63.7) 0.007
Multiple birth (%) 1,738 (35.6) 135 (14.2) <0.0005
Mother smokes (%) 697 (14.3) 118 (12.4) 0.151
Mother smoked during pregnancy (%) 660 (13.5) 108 (11.3) 0.083
Smoking in home (%) 1,375 (28.2) 206 (21.6) <0.0005
≥2 smokers in home (%) 526 (10.8) 97 (10.2) 0.646
≥5 people in household (%) 1,344 (27.5) 214 (22.5) 0.001
Neonatal course
Respiratory support (%) 3,041 (62.3) 401 (42.1) <0.0005
Mean duration of respiratory support (days±SD) 17.2±24.0 29.7±56.9 <0.0005
Oxygen therapy (%) 2,648 (54.3) 437 (45.9) <0.0005
Mean duration of oxygen therapy (days±SD) 25.2±39.7 38.7±72.0 <0.0005
Documented necrotizing enterocolitis (%) 172 (3.5) 20 (2.1) 0.022
Documented sepsis (%) 704 (14.4) 122 (12.8) 0.204
Surgery for patent ductus arteriosus (%) 196 (4.0) 28 (2.9) 0.118
Length of neonatal hospital stay (days±SD) 46.8±71.9 46.9±148.5 0.983
Fig. 1 Medical disorders comprising the special population group (group 2) over four RSV seasons (2006–2010). Dotted lines represent the overall
percentages of each disorder subgroup
836 Eur J Pediatr (2012) 171:833–841(59.6%) received at least four injections of palivizumab. On
average, 38.8% of the infants in group 2 had received
prophylaxis in a prior season.
We defined compliance in two ways: expected number of
doses vs. actual number received and interdose interval. For
expected number of doses, the calculation assumed monthly
injections from the first dose to the end of the RSV season
[28]. For number of days between injections, an interval of
30±5 days was considered compliant. However, an interval
of 20±4 days between the first and second injections likely
results in higher trough levels after the first dose, based on
the pharmacokinetics of the drug and interdose palivizumab
levels achieved in previous studies[24, 38]. Therefore, an
interval of 16–35 days between the first and second injec-
tions was considered compliant. Infants in both groups
received, on average, 92.0±29.9% of the expected number
of injections. A lower prop o r t i o no fg r o u p2i n f a n t s
were compliant with treatment intervals (69.4% vs.
72.6%, p00.048).
As a secondary analysis, interdose interval compliance
was calculated using the 30±5 days that is recommended to
providers. Under these criteria, the overall proportion of
infants that were compliant with treatment drops substan-
tially to 38.5%, with group 2 infants’ compliance lower than
that of group 1 infants (28.2% vs. 40.5%, p<0.0005).
Hospitalizations
In total, 290 (5.0%) infants were hospitalized with an RI, a
total of 322 times, giving an overall hospitalization rate of
5.0%. The majority were admitted for respiratory distress
(63.9%). The average length of stay was 7.5±14.4 days,
with an average of 2.4±13.4 ICU days. There was a signif-
icant difference between groups in the unadjusted propor-
tion hospitalized: 9.0% (95%CI 7.4–11.0) of group 2 infants
were admitted for an RI vs. 4.2% (95%CI 3.7–4.8) of group
1( p<0.0005). Cox proportional hazard analysis confirmed
that group 2 had significantly higher hazard rates (HR02.0,
95%CI 1.5–2.5, B00.675, df01, p<0.0005; Fig. 2a). Com-
pliance, however, was not a significant predictor of hazard
(p00.805), nor was the interaction between group and com-
pliance (p00.722). Subgroups within group 2 showed a
wide variation in hospitalization rates (Table 2), ranging
from 3.4% (cystic fibrosis) to 17.9% (neuromuscular disor-
ders). A chi-squared analysis showed that there was a trend
towards significance when comparing hospitalization rates
among the subsets (χ
2015.5, df08, p00.051).
RSV-positive hospitalizations
Diagnostic tests for RSV were conducted 260 times on 235
infants during 322 hospitalizations. Of these, 70 tests were
positive in 70 patients. Collection methods included nasal
aspirate (49.4%), nasal swab (24.8%), and nasal wash
(2.8%), with 74 cases (23.0%) unreported.
The overall RSV-positive hospitalization rate was
1.48%. There were no significant differences between
infants with and without RSV-positive hospitalization in
the proportions that were fully compliant (85.1% vs.
71.4%, p00.894), nor in the percentage of expected
injections received by each group (92.0±29.9% vs.
88.6±22.7%, p00.333).
Generally, there were no significant differences between
infants in groups 1 and 2 that were hospitalized with an RSV
infection (Table 3). The only exception was with regards to
respiratory support, where a greater proportion of group 2
infants required respiratory support (χ
2010.961, df01, p0
0.002) and generally required support for a longer period of
time (t0−2.122, df024.8, p00.044).
Fig. 2 Cox proportional hazards model looking at time to first hospi-
talization (a) and first RSV hospitalization (b), comparing hazards for
group 1 (solid line) and group 2 (dotted line)
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1.56–3.52) had an RSV-positive hospitalization compared
with group 1 infants (1.32%, 95%CI 1.04–1.68; p00.003).
There was no significant difference between the two groups
in terms of number of days to their first RSV-positive
hospitalization (43.2±38.0 vs. 32.5±40.6, p00.307). In a
Cox proportional hazards model, group 2 had a similar risk
of RSV-positive hospitalization compared with group 1
(HR01.6, 95%CI 0.96–2.86, B00.468, df01, p00.106;
Fig. 2b) and neither compliance (p00.702) nor the interac-
tion of the two (p00.130) significantly affected RSV-
positive hospitalization risk.
Standard indications
A subanalysis was conducted comparing infants in group 2
with infants prophylaxed for all other indications (prematu-
rity, as well as BPD/CLD and CHD) (n06,387). The results
were similar to the original analysis. There was a significant
difference between infants prophylaxed for all standard
indications (prematurity, BPD/CLD, and CHD) and the
special population in terms of proportion with an RI hospi-
talization (5.7% vs. 9.0%, p<0.0005). Similarly, being in
the special population group was associated with an in-
creased HR for RI hospitalization (HR01.5, 95%CI 1.2–
1.9, B00.388, df01, p00.001). A trend was found where a
greater proportion of infants in the special population group
had RSV hospitalizations compared to those with standard
indications (2.35% vs. 1.40%, p00.062) (unadjusted), but
HRs for RSV-positive hospitalization were again similar
(HR01.536, 95%CI 0.889–2.654, B00.429, df01, p00.124).
Discussion
There has been a fourfold riseover the past 4 years from5.6%
to 19.1% in infants receiving palivizumab prophylaxis for
non-approved underlying medical conditions. This was pri-
marily driven by increases in the Down syndrome category
and also by those that were immunized for “other” reasons.
Examples in the latter group include having a twin that qual-
ified for prophylaxis, severe failure to thrive in association
with short bowel syndromes and cholestasis, tracheostomy,
severe obstructive sleep apnea, and complex metabolic disor-
ders. The results suggest that physicians and healthcare pro-
viders are increasingly prescribing palivizumab prophylaxis
Table 2 RI and RSV-positive
hospitalizations across group 2
subpopulations
Cohort with preexisting medical
illnesses who are not currently
approved for RSV prophylaxis
Total Hospitalized Tested Positive RI
hospitalization
rate
RSV
hospitalization
rate
Cardiac 22 2 2 1 9.1 4.55
Pulmonary 127 11 10 2 8.7 1.73
Neuromuscular 78 14 13 5 17.9 6.90
Other 163 14 11 1 8.6 0.78
Multiple 57 8 7 1 14.0 2.01
Immunocompromised 17 2 1 1 11.8 11.8
Airway anomalies 178 18 15 4 10.1 2.70
Down syndrome 193 13 11 3 6.7 1.84
Cystic fibrosis 117 4 3 1 3.4 1.14
Total group 2 952 86 73 19 9.0 2.35
Table 3 Details of RSV-positive hospitalizations in a cohort with
preexisting medical illnesses who are not currently approved for pas-
sive RSV immunization (group 2, n0952) and prophylaxed infants
≤35 weeks gestation without underlying medical disorders who rou-
tinely qualify for RSV prophylaxis according to recommended guide-
lines (group 1, n04,880)
Group 1 Group 2 p value
Mean length of stay (days±SD) 7.3±6.9 7.3±5.8 0.995
Admitted to ICU (%) 15 (29.4) 8 (40.0) 0.411
Mean length of stay in ICU (days±SD) 1.7±3.7 3.3±5.4 0.241
Given respiratory support (%) 10 (19.6) 12 (60.0) 0.002
Mean length of respiratory support (days±SD) 1.0±3.1 3.6±5.0 0.044
Intubated (%) 4 (7.8) 5 (25.0) 0.105
Mean length of intubation (days±SD) 0.7±2.9 1.6±3.6 0.299
Mean lengths of stay are calculated only for those that experienced the event
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ments and provincial guidelines [2].
Differences in demographic information between the two
groups showed that a greater proportion of group 2 infants
were in daycare than group 1. However, this is not unex-
pected, as group 2 infants were, on average, older at the age
of enrolment. While no significant differences were found
between groups relative to expected doses received, a sig-
nificantly lower percentage of group 2 infants received all
their injections within the recommended time intervals.
Group 2 infants were twice as likely to be hospitalized for
both an RI event and RSV infection. This could be due to
lower efficacy of RSV prophylaxis in this population, but
this group also comprises a range of medical disorders and
disease severity and our sample sizes are too small to indi-
vidually elucidate the effect of immunization on RSV hos-
pitalization in each condition. It is more likely that the
severity of the preexisting medical disorder in these patients
makes them generally more susceptible to RIs and perhaps
RSV prophylaxis may modulate the degree of illness, but
this has yet to be determined. While compliance has previ-
ously been shown to be associated with lower RSV-positive
hospitalization rates [18], this was not found in the current
data. However, our results concur with the Palivizumab
Outcomes Registry, which also found no association be-
tween compliance and RSV-positive hospitalization [17].
Higher RSV-positive hospitalization rates have been docu-
mented in infants with other medical conditions. A retro-
spective cohort study of children prophylaxed in Tennessee
reported that, of 3,378 hospitalizations over 4 years, 22.8%
occurred in children with other medical conditions, such as
Down syndrome and neuromuscular disease, while only
12.2% were attributed to prematurity [8]. Similarly, in a
nationwide Japanese survey conducted from 2006 to 2008,
1,115 children aged <4 years who were hospitalized with
RSV did not meet current criteria for prophylaxis. Among
756 infants with underlying disorders, 54.8% had respirato-
ry conditions, 16.5% had neuromuscular impairments, 3.6%
had CHD, 1.6% were immunocompromised, 1.1% had met-
abolic disorders, and 5.3% were documented with other
illnesses [34]. Immunocompromised patients had a signifi-
cantly worse outcome (p<0.0001). There were 16 deaths
and 11 (68.7%) were associated with preexisting medical
disorders. Other studies have found that infants with medi-
cal conditions, such as neuromuscular impairment [47],
Down syndrome [6], cystic fibrosis [1, 23], and immune
dysfunction [22, 29] are at higher risk of hospitalizations
due to RSV infection. Preexisting disease has also been
previously shown to be associated with higher morbidities
and mortality rates due to RSV infection [3, 34, 44, 46].
The limitations of our study include the evaluation of
patients only with specific medical conditions who were
approved individually by provincial Ministries of Health
and enrolled in the CARESS study. The absence of a com-
parative group that did not receive prophylaxis (were either
not prescribed palivizumab or prescribed and did not comply
withtheirprescription) orwerehospitalizedwith RSV prior to
prophylaxis makes it difficult to accurately gauge the effect of
immunizationonthereductionofRSV-relatedhospitalization.
Hospitalized cases were not uniformly tested for RSV, and the
RSV-positive hospitalization rate may be higher than 1.48%.
There were, however, no significant differences between the
premature group and the special population group in terms of
proportions of hospitalized infants tested for RSV (79% vs.
85%, χ
201.179, df01, p00.327). However, strengths of the
studyinclude:stringentsurveillancewitha well-designeddata
collection instrument, comprises the largest subset of
reported infants with characteristic underlying medical
disorders, and provides key information on risk factors
and outcomes in this population over time; the absence
of self-selection bias in that the spectrum of illness in
the study population was diverse without a dispropor-
tionate recruitment of “healthier” infants and the entry
and follow-up end points were clearly defined.
This study indicates that the “special population” infants
with a range of medical disorders who were prophylaxed
have a higher hazard for respiratory hospitalizations than
those who routinely qualify for RSV prophylaxis, according
to recommended guidelines. The difference in these rates is
not related to compliance, though a lower proportion of
infants in the “special population” group were compliant
with treatment than premature infants. However, the special
population had similar hazards for RSV-positive hospital-
izations compared with those who routinely qualify for RSV
prophylaxis. Historically, rates of RSV hospitalizations in
those with underlying illnesses who have not received pro-
phylaxis have been 4- to 14-fold higher than that found in
this prophylaxed cohort [1, 3, 6, 8, 22, 23, 29, 34, 44, 46,
47], though randomized controlled trials would be needed to
make conclusions regarding palivizumab efficacy. While the
strongest evidence supporting the use of palivizumab in
infants with underlying medical illnesses is a randomized,
placebo-controlled clinical trial, the requisite of an extreme-
ly large sample size in each specific medical illness makes it
difficult to execute such studies. In the absence of such data,
registry information can provide preliminary information on
the safety and comparative effectiveness in those with who
receive palivizumab as a result of medical illnesses that
increase the risk of negative respiratory outcomes. Never-
theless, this study encourages healthcare providers to per-
form prospective trials in special populations, for example,
in children with Down syndrome.
In conclusion, this present study shows that palivizumab is
increasingly being used beyond the indications specified by
pediatric advisory guidelines [13, 19, 30, 32, 42], and its
safety in infants with medical disorders has been investigated
Eur J Pediatr (2012) 171:833–841 839in only small clinical trials [7, 14]. This reflects a better
appreciation by healthcare providers of the severity of illness
in these high-risk subpopulations [20, 31] and perhaps the
perceived preventive benefit on the reduction of RSV-positive
hospitalization[15,24]and theconcurrentpotentialmorbidity
and mortality which surpasses the likelihood of causing treat-
ment harm. Therefore, larger prospective studies are urgently
needed to demonstrate the efficacy and safety of palivizumab
and its effect on hospitalizations in these groups of infants.
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